MT 8 - MimeTech/ Recordati

Drug Profile

MT 8 - MimeTech/ Recordati

Alternative Names: MT-8; Negermin methyl ester

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Universita degli Studi di Firenze
  • Developer MimeTech; Recordati
  • Class Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Nerve growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Keratitis
  • Preclinical Dry eyes; Glaucoma; Myocardial infarction; Pressure ulcer; Retinitis pigmentosa; Sickle cell anaemia

Most Recent Events

  • 16 Jun 2017 Recordati in-licenses MT 8 for Neurotrophic keratitis from MimeTech
  • 16 Jun 2017 Phase-I clinical trials in Keratitis in Italy (unspecified route)
  • 16 Jun 2017 Preclinical trials in Dry eyes in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top